NASDAQ · ENLV
Enlivex Therapeutics Ltd.
$2.54-$0.07 (-2.68%)
Enlivex Therapeutics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 99.42% below the high.
Loading market information…
NASDAQ · MTVA · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
MetaVia Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.99% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
MetaVia Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$0.73. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow MetaVia Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00 |
| Q3 2024 | Nov 7, 2024 | -$6.05-637.8% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$2.54-$0.07 (-2.68%)
Enlivex Therapeutics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 99.42% below the high.
$0.38-$0.03 (-7.1%)
Klotho Neurosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.26% below the high.
$3.52+$0.19 (+5.71%)
Passage Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.4% below the high.
$1.01-$0.05 (-4.72%)
Lisata Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.08% below the high.
$1.26-$1.84 (-59.35%)
Sonnet BioTherapeutics Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 93.47% below the high.
$4.40+$0.45 (+11.39%)
CollPlant Biotechnologies Ltd.’s quoted price sits in the lower half of its reported 52-week range, 80.79% below the high.
$1.04-$0.04 (-3.26%)
NuCana plc’s quoted price sits in the lower half of its reported 52-week range, 77.14% below the high.
$0.93-$0.08 (-8.04%)
Exicure, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.14% below the high.
